| Literature DB >> 33165625 |
Shoko Ito1, Shin-Ichiro Fujiwara1, Rui Murahashi1, Hirotomo Nakashima1, Sae Matsuoka1, Takashi Ikeda1, Shin-Ichiro Kawaguchi1, Yumiko Toda1, Tetsuaki Ban1, Takashi Nagayama1, Kento Umino1, Daisuke Minakata1, Kaoru Morita1, Hirofumi Nakano1, Ryoko Yamasaki1, Masahiro Ashizawa1, Chihiro Yamamoto1, Kaoru Hatano1, Kazuya Sato1, Iekuni Oh1, Ken Ohmine1, Yoshinobu Kanda2.
Abstract
Immune thrombocytopenia (ITP) can coexist with autoimmune thyroid disease. However, the detailed clinical features remain unknown. We retrospectively reviewed 248 patients with newly diagnosed ITP in our institute for whom we had thyroid function data at diagnosis between 2000 and 2019. Of the 248 patients with ITP, 74 patients also had thyroid disease, including 36 with overt thyroid disease (13 Graves' disease and 23 Hashimoto's thyroiditis) and 38 with subclinical thyroid disease (3 hyperthyroidism and 35 hypothyroidism). ITP and thyroid disease were concurrently diagnosed in 54 patients. Female sex and positivity for antinuclear antibodies (ANA) were significantly associated with thyroid diseases. Platelet-associated immunoglobulin G (PAIgG) levels in patients with Graves' disease were higher than those in patients with Hashimoto's thyroiditis. Platelet counts were similar among euthyroid patients and patients with thyroid disease. Thrombopoietin-receptor agonist was administered more frequently in patients with thyroid disease. The cumulative incidences of thrombosis and bleeding and overall survival did not differ between patients with and without thyroid disease. Treatment for thyroid disease in 22 patients improved thrombocytopenia in 21 patients, especially in 4 patients who were not treated for ITP. This study demonstrated that thyroid diseases were commonly found in patients with ITP. Treatment of the underlying thyroid disease may improve thrombocytopenia.Entities:
Keywords: Graves’ disease; Hashimoto’s thyroiditis; ITP; Thyroid
Year: 2020 PMID: 33165625 DOI: 10.1007/s00277-020-04343-5
Source DB: PubMed Journal: Ann Hematol ISSN: 0939-5555 Impact factor: 3.673